Pluristem Gets U.S. Patent For Production Ways And Use Of Placental Cell Therapy

(RTTNews) - Placenta-based cell therapy products developer Pluristem Therapeutics Inc. (PSTI) announced that the U.S. Patent and Trademark Office has issued to the company patent no. 9,096,827 titled "Adherent Cells From Placenta Tissue and Use Thereof in Therapy".

The patent protects specific methods of culturing placental adherent stromal cells, and use of these cells for the treatment of a wide variety of diseases.

Indications covered by the patent include a wide range of ischemic conditions such as heart disease, stroke, peripheral arterial disease (which includes critical limb ischemia and intermittent claudication), graft-versus-host disease, solid organ transplantation, hematopoietic stem cell transplantation, diabetes, autoimmune diseases, neuropathic pain and cancer.

Pluristem has been issued over 40 patents worldwide, and has about 150 more patents pending.